These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33367372)

  • 1. PD-L1 cellular nanovesicles carrying rapamycin inhibit alloimmune responses in transplantation.
    Yang M; Xu Z; Yan H; Tsai HI; Su D; Yan F; Lu Q; Feng J; Zeng W; Xi L; Zha H; Ling Y; He C; Wu Y; Xu X; Zheng G; Liu G; Chen H; Cheng F
    Biomater Sci; 2021 Feb; 9(4):1246-1255. PubMed ID: 33367372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering Programmed Death Ligand-1/Cytotoxic T-Lymphocyte-Associated Antigen-4 Dual-Targeting Nanovesicles for Immunosuppressive Therapy in Transplantation.
    Xu Z; Tsai HI; Xiao Y; Wu Y; Su D; Yang M; Zha H; Yan F; Liu X; Cheng F; Chen H
    ACS Nano; 2020 Jul; 14(7):7959-7969. PubMed ID: 32515579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death-1 targeting can promote allograft survival.
    Ozkaynak E; Wang L; Goodearl A; McDonald K; Qin S; O'Keefe T; Duong T; Smith T; Gutierrez-Ramos JC; Rottman JB; Coyle AJ; Hancock WW
    J Immunol; 2002 Dec; 169(11):6546-53. PubMed ID: 12444166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy.
    Xu X; Liu L; Wang H; Li W; Zou Y; Zeng Y; Yang Q; Bai D; Dai D
    ACS Biomater Sci Eng; 2022 Nov; 8(11):4819-4826. PubMed ID: 36206367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism.
    Lee I; Wang L; Wells AD; Ye Q; Han R; Dorf ME; Kuziel WA; Rollins BJ; Chen L; Hancock WW
    J Immunol; 2003 Dec; 171(12):6929-35. PubMed ID: 14662900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically engineered PD-1 displaying nanovesicles for synergistic checkpoint blockades and chemo-metabolic therapy against non-small cell lung cancer.
    Li B; Yang T; Liu J; Yu X; Li X; Qin F; Zheng J; Liang J; Zeng Y; Zhou Z; Liu L; Zhang B; Yao W; Feng Z; Zeng G; Zhou Q; Chen L
    Acta Biomater; 2023 Apr; 161():184-200. PubMed ID: 36893957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.
    Sandner SE; Clarkson MR; Salama AD; Sanchez-Fueyo A; Domenig C; Habicht A; Najafian N; Yagita H; Azuma M; Turka LA; Sayegh MH
    J Immunol; 2005 Mar; 174(6):3408-15. PubMed ID: 15749874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
    Li L; Miao Q; Meng F; Li B; Xue T; Fang T; Zhang Z; Zhang J; Ye X; Kang Y; Zhang X; Chen Q; Liang X; Chen H; Zhang X
    Theranostics; 2021; 11(12):6033-6043. PubMed ID: 33897897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells.
    Wang C; Yi T; Qin L; Maldonado RA; von Andrian UH; Kulkarni S; Tellides G; Pober JS
    J Clin Invest; 2013 Apr; 123(4):1677-93. PubMed ID: 23478407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered Small Extracellular Vesicles as a FGL1/PD-L1 Dual-Targeting Delivery System for Alleviating Immune Rejection.
    Tsai HI; Wu Y; Liu X; Xu Z; Liu L; Wang C; Zhang H; Huang Y; Wang L; Zhang W; Su D; Khan FU; Zhu X; Yang R; Pang Y; Eriksson JE; Zhu H; Wang D; Jia B; Cheng F; Chen H
    Adv Sci (Weinh); 2022 Jan; 9(3):e2102634. PubMed ID: 34738731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction.
    Shi XL; Mancham S; Hansen BE; de Knegt RJ; de Jonge J; van der Laan LJ; Rivadeneira F; Metselaar HJ; Kwekkeboom J
    J Hepatol; 2016 Jun; 64(6):1274-82. PubMed ID: 26941095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
    Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
    Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascularized composite allograft rejection is delayed by infusion of IFN-γ-conditioned BMSCs through upregulating PD-L1.
    Wang Y; Xi Y; Han F; Liu Y; Li N; Ren Z; Xue J; Guo L; Hu D
    Cell Tissue Res; 2019 May; 376(2):211-220. PubMed ID: 30613905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival.
    Shen L; Jin Y; Freeman GJ; Sharpe AH; Dana MR
    J Immunol; 2007 Sep; 179(6):3672-9. PubMed ID: 17785803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 Cellular Nanovesicles Carrying Gemcitabine to Inhibit the Proliferation of Triple Negative Breast Cancer Cell.
    Zha H; Xu Z; Xu X; Lu X; Shi P; Xiao Y; Tsai HI; Su D; Cheng F; Cheng X; Chen H
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade or deficiency of PD-L1 expression in intestinal allograft accelerates graft tissue injury in mice.
    Matsushima H; Morita-Nakagawa M; Datta S; Pavicic PG; Hamilton TA; Abu-Elmagd K; Fujiki M; Osman M; D'Amico G; Eguchi S; Hashimoto K
    Am J Transplant; 2022 Mar; 22(3):955-965. PubMed ID: 34679256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 induces macrophage polarization toward the M2 phenotype via Erk/Akt/mTOR.
    Wei Y; Liang M; Xiong L; Su N; Gao X; Jiang Z
    Exp Cell Res; 2021 May; 402(2):112575. PubMed ID: 33771483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 and PD-L1 expression in cardiac transplantation.
    Bishawi M; Bowles D; Pla MM; Oakes F; Chiang Y; Schroder J; Milano C; Glass C
    Cardiovasc Pathol; 2021; 54():107331. PubMed ID: 33737091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.